MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-29-2023
Chembio Diagnostics Market Cap 2011-2025 | CEMI
As of December 25, 2025 Chembio Diagnostics has a market cap of $ 16.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 M | 27.7 M | 132 M | 67.8 M | 101 M | 102 M | 57.9 M | 47 M | 35.6 M | 32.8 M | 41.9 M | 29.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 12.6 M | 57.4 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
DexCom
DXCM
|
48.8 B | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
9.32 B | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Danaher Corporation
DHR
|
152 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
521 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
399 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
70.8 K | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Guardant Health
GH
|
5.84 B | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
1.53 B | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Mettler-Toledo International
MTD
|
29.9 B | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
16.4 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
8.54 B | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.2 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
OPKO Health
OPK
|
1.21 B | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Pacific Biosciences of California
PACB
|
1.41 B | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
19.1 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Myriad Genetics
MYGN
|
973 M | $ 6.55 | -0.15 % | $ 593 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
21.1 B | $ 254.46 | 0.52 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 183.68 | 0.33 % | $ 15.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
37.7 B | $ 688.18 | 0.86 % | $ 56.8 B | USA |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 66.68 | 0.23 % | $ 4.61 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 138.32 | -0.03 % | $ 42 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
Biomerica
BMRA
|
7.19 M | $ 2.65 | 1.15 % | $ 6.09 M | USA |